Navigation Links
Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
Date:2/7/2013

SUNNYVALE, Calif., Feb. 7, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will report financial results and recent developments for its three and six months ended December 31, 2012  after the NASDAQ Market closes on Thursday, February 14, 2013.  The Company will conduct a conference call and audio webcast at 4:30 p.m ET on the same day. As previously announced, the Company changed its fiscal year end from June 30 to December 31, effective December 31, 2012. As a result, the six months ended December 31, 2012 represent a transition period, with the next fiscal year covering the period from January 1, 2013 through December 31, 2013.

Conference call and webcast details:

Date: February 14, 2013
Time: 4:30 PM ET
Listen via Internet: http://ir.pharmacyclics.com/events.cfm
Toll-free: (877)-407-0778
International: (201)-689-8565

Replay Number (Toll Free): (877)-660-6853
Replay Number (International): (201)-612-7415
Conference ID #: 409002

A webcast replay will be available on the Pharmacyclics website for 30 days.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when
'/>"/>

SOURCE PHARMACYCLICS/ ACCOUNTS PAYABLE
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
2. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
3. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
4. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
5. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
6. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
7. Misonix Announces New Distribution Agreement For Panama
8. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
9. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
10. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
11. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a developer ... is now included in the Russell 3000®, the Russell ... to the indexes occurred at the close of trading ... its comprehensive set of U.S. and global indexes. ... Cap and Global Indexes coincides with the progress we ...
(Date:6/29/2015)... , June 29, 2015  Relmada Therapeutics, ... therapies for the treatment of chronic pain, announced ... study with novel formulations of oral, enteric-coated buprenorphine ... chronic pain and opioid dependence indications has reached ... company anticipates reporting top-line results in the second ...
(Date:6/29/2015)... England , June 29, 2015  Eli ... Immunocore Limited today announced that they have entered ... the utility of Immunocore,s lead T cell receptor-based ... (LY2157299) and merestinib (LY2801653) for the treatment of ... identify combination regimens that provide synergies in efficacy ...
Breaking Medicine Technology:Trovagene Upgraded to Russell 3000, Small Cap and Global Indexes 2Trovagene Upgraded to Russell 3000, Small Cap and Global Indexes 3Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark 2Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark 3Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 2Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 3Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 4Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 5Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 6Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma 7
... Seating & Mobility (USM) is excited to announce today ... (CKM) to acquire and merge its complex mobility business with ... as central, eastern and southern Kentucky. "The addition ... a core market for us and supports our regional initiative. ...
... Clinical Diagnostics (OCD) today announced the launch of ... that delivers high-quality, reliable test results for mid- ... that drive reliability and efficiency throughout OCD,s portfolio ... x600 Family of Systems, which includes the VITROS® ...
Cached Medicine Technology:Ortho Clinical Diagnostics Launches VITROS® 4600 Chemistry System for Mid- to High-Volume Laboratories 2Ortho Clinical Diagnostics Launches VITROS® 4600 Chemistry System for Mid- to High-Volume Laboratories 3Ortho Clinical Diagnostics Launches VITROS® 4600 Chemistry System for Mid- to High-Volume Laboratories 4
(Date:6/29/2015)... (PRWEB) , ... June 29, 2015 , ... ... the news that the European Medicines Agency (EMA) has granted accelerated approval of ... remains a global public health threat and the approval of nivolumab for patients ...
(Date:6/29/2015)... ... 29, 2015 , ... World Patent Marketing, a vertically integrated ... invention that makes parenthood less tiring without sacrificing your child's well being. , ... USD 52.2 billion in 2017," says Scott Cooper, CEO and Creative Director of ...
(Date:6/29/2015)... ... June 29, 2015 , ... Two multicounty litigations ... Bard, Inc. and Ethicon, Inc. continue to move forward in New Jersey’s Bergen ... is to be convened on Thursday, July 23rd at 12:00 p.m. (In re: ...
(Date:6/29/2015)... ... June 29, 2015 , ... OR Manager announced Monday the launch of an ... well as a redesigned logo and weekly eLetter. The website contains the same informational ... and easier to navigate. , In addition to a refreshed look, http://www.ormanager.com ...
(Date:6/29/2015)... ... June 29, 2015 , ... Celebrities have many skincare secrets, and skin expert, ... summer long and beyond. People don’t have to be famous to have fabulous ... maintain an even skin tone, avoid breakouts, and take skin health and wellness to ...
Breaking Medicine News(10 mins):Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 3Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 2Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 3Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 4Health News:Bringing Up Baby...Millenials Should Check World Patent Marketing's New Baby Invention 5Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 3Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 4Health News:OR Manager Launches New Website 2Health News:Skin Guru Shares Celebrity FACE Secrets For Summer-Proofing The Skin 2Health News:Skin Guru Shares Celebrity FACE Secrets For Summer-Proofing The Skin 3
... if they also have diagnosed or undiagnosed obstructive sleep ... study presented April 28, 2009, at the American Academy ... Stead, M.D., professor and chair of the Department of ... and professor of Neurosurgery, reported the findings at AAN, ...
... nutrition counseling for virtually all overweight and obese women ... excess weight for mothers and children alike, according to ... Association and the American Society of Nutrition. , ... Journal of the American Dietetic Association , represents ...
... to enhance management of osteoporosisNEW YORK, April 28 ... that it will offer a new risk assessment ... help physicians identify patients at risk for osteoporosis ... http://www.newscom.com/cgi-bin/prnh/20090428/NY06275 ) ...
... above and beyond in community service effortsPITTSBURGH, April 28 ... volunteers with a Jefferson Award for Public Service for ... their community service efforts. A corporate champion of the ... five companies in Pennsylvania with the privilege of acknowledging ...
... health leaders work vigorously to consider action to combat ... Association says taking simple precautions can help consumers stay ... take seriously," said Chris Cathcart, CSPA President. "There are ... and their families healthy now and throughout the year ...
... who may have overpaid for certain prescription drugs ... from a class action settlement. But the ... Here are the details.Listen to this report from ... http://inr.mediaseed.tv/oneClip_C/Default.aspx?feed=IcBjaHB5bt9KezTTiXLKRhDhe4FyCPUN Registered journalists can access video, ...
Cached Medicine News:Health News:Poor sleep quality leads to poorer prognosis after stroke 2Health News:ADA releases position paper on obesity, reproduction and pregnancy outcomes 2Health News:Phreesia Works With Osteoporosis Experts to Expand its Measurement Guided Care Program 2Health News:Phreesia Works With Osteoporosis Experts to Expand its Measurement Guided Care Program 3Health News:Highmark Inc. Recognizes Exceptional Employee Volunteers with Jefferson Awards for Public Service 2Health News:Highmark Inc. Recognizes Exceptional Employee Volunteers with Jefferson Awards for Public Service 3Health News:Highmark Inc. Recognizes Exceptional Employee Volunteers with Jefferson Awards for Public Service 4Health News:Highmark Inc. Recognizes Exceptional Employee Volunteers with Jefferson Awards for Public Service 5Health News:Highmark Inc. Recognizes Exceptional Employee Volunteers with Jefferson Awards for Public Service 6Health News:Highmark Inc. Recognizes Exceptional Employee Volunteers with Jefferson Awards for Public Service 7Health News:Swine Influenza Outbreak - How to Stay Healthy 2
Solid lower plate with outside width 15 mm. Open serrated upper plate with inside dimensions 9 x 12 mm. Serrated handle with locking thumb screw and polished finish....
Narrow smooth jaws. Serrated handle with polished finish....
14 mm oval solid lower plate and straight 9 mm serrated upper jaw. Locking thumb screw and serrated handle with polished finish....
Round solid 10 mm wide lower plate. Open upper plate with inside diameter 8 mm. Serrated handle with locking thumb screw and polished finish. Most popular size or model....
Medicine Products: